Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?

dc.authorid0000-0001-9636-4113
dc.authorid0000-0001-6826-7818
dc.authorid0000-0003-1508-2822
dc.authorid0000-0002-7424-8688
dc.authorid0000-0003-1237-8281
dc.authorid0000-0002-2035-9462
dc.contributor.authorSerin, İstemi
dc.contributor.authorSevindik, Ömür Gökmen
dc.contributor.authorBalık Aydın, Berrin
dc.contributor.authorMelek, Elif
dc.contributor.authorMutlu, Yaşa Gül
dc.contributor.authorBilgen, Hülya
dc.contributor.authorBeköz, Hüseyin
dc.contributor.authorKaynar, Leylagül
dc.date.accessioned2024-01-12T12:27:43Z
dc.date.available2024-01-12T12:27:43Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractPlerixafor increases stem cell mobilization by reversibly binding to the chemokine receptor CXCR4. In our study, we examined the results of mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) and revealed their effects on autologous stem cell transplantation (ASCT) engraftment kinetics. The study included all cases of ASCT performed in the Adult Bone Marrow Transplantation Unit of xxx University between January 2014 and January 2022. It included a total of 300 patients. The total number of CD34 + cells collected was 7.44 +/- 4.19 in patients with plerixafor and 9.53 +/- 6.09 in patients without plerixafor. The mean neutrophil and platelet engraftment took longer in plerixafor-mobilized patients (neutrophil: 12 +/- 4.1 vs. 10.2 +/- 2.7 days; platelet: 21.6 +/- 13.9 vs. 14.2 +/- 5.9 days; p = 0.008 and p = 0.002). The number of febrile neutropenia attacks was significantly higher in plerixafor-mobilized patients (p = 0.04). In the chemo-mobilized patient subgroup, plerixafor-mobilized patients experienced more febrile neutropenia attacks (p = 0.04). The mean time to both neutrophil and platelet engraftment was longer in patients mobilized with plerixafor. In the subgroup of patients with MM, the mean time to platelet engraftment was longer in patients mobilized with plerixafor. Plerixafor and its effect on engraftment kinetics should be evaluated with further studies in a larger population with survival analysis.
dc.identifier.citationSerin, İ., Sevindik, Ö. G., Balık Aydın, B., Melek, E., Mutlu, Y. G., Bilgen, H. ... Kaynar, L. (2023). Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics? Transfusion and Apheresis Science, 62(6). https://dx.doi.org/10.1016/j.transci.2023.103809
dc.identifier.doi10.1016/j.transci.2023.103809
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue6
dc.identifier.pmid37690861
dc.identifier.scopus2-s2.0-85171162175
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://dx.doi.org/10.1016/j.transci.2023.103809
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12134
dc.identifier.volume62
dc.identifier.wos001132183900001en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorSevindik, Ömür Gökmen
dc.institutionauthorBalık Aydın, Berrin
dc.institutionauthorMelek, Elif
dc.institutionauthorMutlu, Yaşa Gül
dc.institutionauthorBilgen, Hülya
dc.institutionauthorBeköz, Hüseyin
dc.institutionauthorKaynar, Leylagül
dc.language.isoen
dc.publisherElsevier Ltd
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPlerixafor
dc.subjectStem Cell Transplantation
dc.subjectMobilization
dc.subjectEngraftment
dc.subjectPrognosis
dc.titlePlerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: